Bruce L Levine1. 1. The University of Pennsylvania School of Medicine, Hospital of University of Pennsylvania, Department of Pathology and Laboratory Medicine, M6.40 Maloney, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. LevineBL@mail.med.upenn.edu
Abstract
BACKGROUND: Basic research contributions towards the molecular and cellular understanding of immune mediated control of cancer and infectious diseases have created opportunities to develop new forms of T-cell-based vaccination for cancer and chronic infections like HIV. In the past two decades, there has been a dramatic increase in the number of cell therapy clinical trials around the world aimed at enhancing antitumor immunity, restoring immune function to infectious diseases and augmenting vaccine efficacy. OBJECTIVE: To provide a review of new and emerging methods of T lymphocyte engineering, gene transfer to T cells and clinical trials. METHODS: A review of recent clinical trials, along with a brief historical perspective, with a focus on challenges and recent advances in the field and requirements for successful T-cell therapies. CONCLUSION: Advances in the technological approaches and methods for ex vivo manipulation have led to T lymphocytes endowed with enhanced potency and unique functions, with promise as the new generation of infused therapeutics.
BACKGROUND: Basic research contributions towards the molecular and cellular understanding of immune mediated control of cancer and infectious diseases have created opportunities to develop new forms of T-cell-based vaccination for cancer and chronic infections like HIV. In the past two decades, there has been a dramatic increase in the number of cell therapy clinical trials around the world aimed at enhancing antitumor immunity, restoring immune function to infectious diseases and augmenting vaccine efficacy. OBJECTIVE: To provide a review of new and emerging methods of T lymphocyte engineering, gene transfer to T cells and clinical trials. METHODS: A review of recent clinical trials, along with a brief historical perspective, with a focus on challenges and recent advances in the field and requirements for successful T-cell therapies. CONCLUSION: Advances in the technological approaches and methods for ex vivo manipulation have led to T lymphocytes endowed with enhanced potency and unique functions, with promise as the new generation of infused therapeutics.
Authors: Douglas W McMillin; Jake Delmore; Joseph M Negri; Matthew Vanneman; Shohei Koyama; Robert L Schlossman; Nikhil C Munshi; Jacob Laubach; Paul G Richardson; Glenn Dranoff; Kenneth C Anderson; Constantine S Mitsiades Journal: Blood Date: 2012-01-30 Impact factor: 22.113
Authors: Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton Journal: Immunol Res Date: 2010-12 Impact factor: 2.829
Authors: Jacob A Klapper; Armen A Thomasian; Douglas M Smith; Gayle C Gorgas; John R Wunderlich; Franz O Smith; Brian S Hampson; Steven A Rosenberg; Mark E Dudley Journal: J Immunol Methods Date: 2009-04-21 Impact factor: 2.303
Authors: Chrystal M Paulos; Megan M Suhoski; Gabriela Plesa; Tianying Jiang; Samik Basu; Tatiana N Golovina; Shuguang Jiang; Nicole A Aqui; Daniel J Powell; Bruce L Levine; Richard G Carroll; James L Riley; Carl H June Journal: Immunol Res Date: 2008 Impact factor: 2.829
Authors: Angel Varela-Rohena; Carmine Carpenito; Elena E Perez; Max Richardson; Richard V Parry; Michael Milone; John Scholler; Xueli Hao; Angela Mexas; Richard G Carroll; Carl H June; James L Riley Journal: Immunol Res Date: 2008 Impact factor: 2.829
Authors: Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo Journal: Blood Date: 2009-06-26 Impact factor: 22.113